Sofosbuvir/velpatasvir

Drug Profile

Sofosbuvir/velpatasvir

Alternative Names: Epclusa; Fixed-dose combination of sofosbuvir and GS-5816 - Gilead Sciences; GS 5816/sofosbuvir; GS 7977/GS 5816; SOF/GS-5816; SOF/VEL; Sofosbuvir/GS 5816; Velpatasvir/sofosbuvir

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Carbamates; Chromans; Imidazoles; Naphthols; Phenylacetates; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 10 Mar 2017 Gilead Sciences plans a phase III trial for Hepatitis C (NCT03074331)
  • 06 Mar 2017 Gilead Sciences plans a phase III trial for Hepatitis C in India (CTRI2017-02-007798)
  • 27 Feb 2017 Gilead Sciences has patent protection for sofosbuvir and velpatasvir in European Union (Gilead Sciences form 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top